ArticleFEMS microbiology ecology2025
Milk and mucin glycans orchestrate a synthetic infant gut microbiota structure.
Article in FEMS microbiology ecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bifidobacterial enzyme orchestrates ecology and function of infant gut bacterial community.bioRxiv : the preprint server for biology · 2026Article
- Selected Protective Mechanisms of Human Milk Against Intestinal Protozoal Infections in Infants.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glycans are crucial for infant gut microbiota development. Human milk contains prebiotic human milk oligosaccharides (HMOs) that stimulate gut microbes. Simultaneously, the glycan-rich mucus layer develops and attracts mucin glycan-degrading bacteria. As HMOs and mucin are degraded by homologous enzymes, bacterial glycan-degrading abilities overlap. However, less is known about how infant gut microbial communities form when both types of glycans are available. To study this, we created a synthetic community with specialist glycan degraders and cross-feeders from the infant gut (BabyBac). We evaluated it in different in vitro conditions including combinations of diet-derived [HMOs, galactooligosaccharides (GOS), and fructooligosaccharides (FOS)] and mucus glycans. Glycan combinations significantly affected the community composition and metabolic output. The glycan type affected the overall community, with mucin and HMOs being the top drivers of variation. HMOs favoured glycan degraders and cross-feeders, whereas mucin glycan degrader Akkermansia muciniphila was outcompeted. Conversely, when mucin was present, A. muciniphila thrived. Addition of mucin monomers and 2'-FL to GOS/FOS did not reinstate A. muciniphila abundance. This suggests that A. muciniphila cannot compete with infant-related bacteria without the complete mucin structure. Overall, our findings suggest that the interplay between dietary and mucus glycans creates niche differentiation in the infant gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.